Your browser doesn't support javascript.
loading
Medium-Term Weight Loss and Remission of Comorbidities Following Endoscopic Sleeve Gastroplasty: a Systematic Review and Meta-analysis.
Fehervari, Matyas; Fadel, Michael G; Alghazawi, Laith Omar Khalaf; Das, Bibek; Rodríguez-Luna, María Rita; Perretta, Silvana; Wan, Andrew; Ashrafian, Hutan.
Affiliation
  • Fehervari M; Department of Surgery and Cancer, Imperial College London, London, UK. matyas.fehervari15@imperial.ac.uk.
  • Fadel MG; Department of Upper Gastrointestinal and Bariatric Surgery, St. George's University Hospitals NHS Foundation Trust, London, UK. matyas.fehervari15@imperial.ac.uk.
  • Alghazawi LOK; IHU-Strasbourg, Institute of Image-Guided Surgery, Strasbourg, France. matyas.fehervari15@imperial.ac.uk.
  • Das B; Department of Surgery and Cancer, Imperial College London, London, UK.
  • Rodríguez-Luna MR; Department of Surgery and Cancer, Imperial College London, London, UK.
  • Perretta S; Department of Surgery and Cancer, Imperial College London, London, UK.
  • Wan A; Research Institute against Digestive Cancer (IRCAD), Strasbourg, France.
  • Ashrafian H; ICube Laboratory, Photonics Instrumentation for Health, Strasbourg, France.
Obes Surg ; 33(11): 3527-3538, 2023 11.
Article in En | MEDLINE | ID: mdl-37700147
ABSTRACT
This systematic review and meta-analysis aimed to determine the short- and medium-term weight loss outcomes and comorbidity resolution following endoscopic sleeve gastroplasty. Our search identified 35 relevant studies containing data from 7525 patients. Overall, pooled short-term (12 months) total weight loss (TWL) was 16.2% (95% CI 13.1-19.4%) in 23 studies (n = 5659). Pooled medium-term TWL was 15.4% (95% CI 13.7-17.2%) in 10 studies (n = 4040). Diabetes resolution was 55.4% (95% CI 46-64%), hypertension resolution was 62.8% (95% CI 43-82%), dyslipidaemia resolution was 56.3% (95% CI 49-63%), and obstructive sleep apnoea resolution was 51.7% (95% CI 16.2-87.3%) in four studies (n = 480). This pooled analysis demonstrates that ESG can induce durable weight loss and resolution of obesity-associated comorbidities in patients with moderate obesity.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Obesity, Morbid / Gastroplasty Type of study: Systematic_reviews Limits: Humans Language: En Year: 2023 Type: Article

Full text: 1 Database: MEDLINE Main subject: Obesity, Morbid / Gastroplasty Type of study: Systematic_reviews Limits: Humans Language: En Year: 2023 Type: Article